Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 05 Jul 2024
An online pharmacy pledged to make prescriptions easier. It sent the wrong drugs instead.
4 July 2024 - Elevance’s CarelonRx customers waited weeks for prescriptions or received medications that could have harmed them. ...
Posted by Michael Wonder on 05 Jul 2024
CSL Behring announces first two patients treated with Hemgenix (etranacogene dezaparvovec) gene therapy for haemophilia B in Europe
4 July 2024 - CSL Behring today announced that two haemophilia B patients were treated with the gene therapy Hemgenix ...
Posted by Michael Wonder on 05 Jul 2024
Tagrisso with the addition of chemotherapy approved in the EU as new first-line treatment for patients with EGFR-mutated advanced lung cancer
5 July 2024 - Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly ...
Posted by Michael Wonder on 05 Jul 2024
Dutch Minister plans to implement new reimbursement system for high cost medicine
27 June 2024 - Concerns have been raised about the relative effectiveness of an increasing number of new medicines at ...
Posted by Michael Wonder on 05 Jul 2024
PHARMAC opens first consultation for cancer medicines after funding boost
5 July 2024 - PHARMAC is looking to widen access to four medicines as part of the first public consultation ...
Posted by Michael Wonder on 04 Jul 2024
RSV vaccination: protecting older people from serious complications
4 July 2024 - Referred by the Ministry of Health, the High Authority for Health has assessed the opportunity to integrate ...
Posted by Michael Wonder on 04 Jul 2024
Gyre Therapeutics announces China’s NMPA approval of avatrombopag maleate tablets for the treatment of CLD associated thrombocytopenia
2 July 2024 - Gyre Therapeutics today announced that China’s National Medical Products Administration has approved Gyre Pharmaceuticals’ avatrombopag maleate tablets ...
Posted by Michael Wonder on 04 Jul 2024
St Vincent’s splits with insurer NIB amid private hospitals ‘crisis’
4 July 2024 - Australia’s largest non-profit hospital operator says Labor is yet to fully grapple with a crisis facing ...
Posted by Michael Wonder on 04 Jul 2024
Lisocabtagene maraleucel for the treatment of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
4 July 2024 - NICE is unable to make a recommendation on the use of lisocabtagene maraleucel (Breyanzi) in the NHS ...
Posted by Michael Wonder on 04 Jul 2024
Checkpoint Therapeutics announces biologics license application resubmission for cosibelimab
2 July 2024 - Checkpoint Therapeutics today announced it has completed the resubmission of its biologics license application to the US ...
Posted by Michael Wonder on 04 Jul 2024
Zilucoplan sodium for the treatment of patients with generalised antibody positive myasthenia gravis
4 July 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 04 Jul 2024
Hutchmed announces NDA acceptance in China for tazemetostat for the treatment of relapsed or refractory follicular lymphoma with priority review status
4 July 2024 - - Hutchmed (China) today announces that the new drug application for tazemetostat for the treatment of ...
Posted by Michael Wonder on 04 Jul 2024
Full-Life Technologies granted FDA fast track designation for 225Ac-FL-020 for the treatment of metastatic castration resistant prostate cancer
2 July 2024 - Full-Life Technologies today announced that the US FDA has granted fast track designation for 225Ac-FL-020, the company's ...
Posted by Michael Wonder on 04 Jul 2024
Health Canada authorises Rybrevant (amivantamab) in combination with carboplatin and pemetrexed as the only targeted first-line treatment approved for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
3 July 2024 - Phase 3 PAPILLON study showed Rybrevant in combination with carboplatin and pemetrexed significantly improved progression-free survival, ...
Posted by Michael Wonder on 03 Jul 2024
HAS clarifies the framework of the “bet” on early access to medicines
24 June 2024 - Committed to a process of continuous development of its methods, the High Authority of Health is launching ...